Skip to main content

Advertisement

SpringerLink
Log in

R0 Resection in Recurrent Gynecologic Malignancy: Pelvic Exenteration and Beyond

  • Gynecologic Cancers (JS Ferriss, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Pelvic exenteration is a radical surgery, but oftentimes, it is the last curative option for patients with recurrent gynecologic malignancies who have exhausted more conservative therapies. Mortality and morbidity outcomes have improved over time, but there are still significant peri-operative risks. Considerations before pursing pelvic exenteration must include the likelihood of oncologic cure and patients’ fitness to undergo such a procedure, particularly given the high rate of surgical morbidity. Pelvic sidewall tumors have been a traditional contraindication for pelvic exenteration due to the difficulty in obtaining negative margins, but the use of laterally extended endopelvic resection and intra-operative radiation therapy allows for more radical resection of recurrent disease. We believe that these procedures to achieve R0 resection can expand the use of curative-intent surgery in recurrent gynecologic cancer, but require the surgical expertise of colleagues in orthopedic and vascular surgery and collaboration with plastic surgery for complex reconstruction and optimization of post-operative healing. Surgery of recurrent gynecologic cancer including pelvic exenteration, requires careful patient selection, pre-operative medical optimization and prehabilitation, and thorough counseling to optimize outcomes, both oncologic and peri-operative. We believe the creation of a well-developed team, including surgical teams and supportive care services, can lead to the best patient outcomes and improved professional satisfaction amongst providers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma; a one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1(2):177–83.

    Article  CAS  PubMed  Google Scholar 

  2. Lampe B, Luengas-Würzinger V, Weitz J, Roth S, Rawert F, Schuler E, et al. Opportunities and limitations of pelvic exenteration surgery. Cancers. 2021;13(24):6162.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sardain H, Lavoue V, Redpath M, Bertheuil N, Foucher F, Levêque J. Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy A systematic review. Eur J Surg Oncol (EJSO). 2015;41(8):975–85.

    Article  CAS  PubMed  Google Scholar 

  4. Diver EJ, Rauh-Hain JA, Del Carmen MG. Total pelvic exenteration for gynecologic malignancies. Int J Surg Oncol. 2012;2012.

  5. Nielsen CKP, Sørensen MM, Christensen HK, Funder JA. Complications and survival after total pelvic exenteration. Eur J Surg Oncol. 2022.

  6. Exenteration for gynecologic cancer [Internet]. 2022 [cited 7/26/2022]. Available from: https://www.uptodate.com/contents/exenteration-for-gynecologic-cancer.

  7. Kaur M, Joniau S, D’Hoore A, Vergote I. Indications, techniques and outcomes for pelvic exenteration in gynecological malignancy. Curr Opin Oncol. 2014;26(5):514–20.

    Article  PubMed  Google Scholar 

  8. Stanhope CR, Symmonds RE. Palliative exenteration—what, when, and why? Am J Obstet Gynecol. 1985;152(1):12–6.

    Article  CAS  PubMed  Google Scholar 

  9. Benn T, Brooks R, Zhang Q, Powell M, Thaker P, Mutch D, et al. Pelvic exenteration in gynecologic oncology: a single institution study over 20 years. Gynecol Oncol. 2011;122(1):14–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Seebacher V, Rockall A, Nobbenhuis M, Sohaib SA, Knogler T, Alvarez RM, et al. The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study. Arch Gynecol Obstet. 2022;305(5):1343–52. This is the first study to evaluate the prognostic significance of nutritional risk factors and sarcopenia in patients undergoing pelvic exenteration for recurrent gynecologic malignancies.

  11. Westin SN, Rallapalli V, Fellman B, Urbauer DL, Pal N, Frumovitz MM, et al. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014;134(3):546–51.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Haidopoulos D, Pergialiotis V, Aggelou K, Thomakos N, Alexakis N, Stamatakis E, et al. Pelvic exenteration for gynecologic malignancies: the experience of a tertiary center from Greece. Surg Oncol. 2022;40:101702.

    Article  PubMed  Google Scholar 

  13. Ter Glane L, Hegele A, Wagner U, Boekhoff J. Pelvic exenteration for recurrent or advanced gynecologic malignancies–analysis of outcome and complications. Gynecol Oncol Rep. 2021;36:100757.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Marnitz S, Köhler C, Müller M, Behrens K, Hasenbein K, Schneider A. Indications for primary and secondary exenterations in patients with cervical cancer. Gynecol Oncol. 2006;103(3):1023–30.

    Article  PubMed  Google Scholar 

  15. Park JY, Choi HJ, Jeong SY, Chung J, Park JK, Park SY. The role of pelvic exenteration and reconstruction for treatment of advanced or recurrent gynecologic malignancies: analysis of risk factors predicting recurrence and survival. J Surg Oncol. 2007;96(7):560–8.

    Article  PubMed  Google Scholar 

  16. Straubhar AM, Chi AJ, Zhou QC, Iasonos A, Filippova OT, Leitao MM Jr, et al. Pelvic exenteration for recurrent or persistent gynecologic malignancies: clinical and histopathologic factors predicting recurrence and survival in a modern cohort. Gynecol Oncol. 2021;163(2):294–8.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Peiretti M, Zapardiel I, Zanagnolo V, Landoni F, Morrow C, Maggioni A. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012;21(2):e59–66.

    Article  CAS  PubMed  Google Scholar 

  18. Baiocchi G, Guimaraes GC, Faloppa CC, Kumagai LY, Oliveira RAR, Begnami MD, et al. Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? Ann Surg Oncol. 2013;20(5):1694–700.

    Article  PubMed  Google Scholar 

  19. Sabiani L, Knight S, Blache G, Jauffret C, Buttarelli M, Lambaudie E, et al. Operative prognostic scores for pelvic exenterations for gynecological cancer: when should we operate. J Surg Res. 2022;5:449–55. This is a large single center retrospective study consisting of 277 patients which evaluated prognostic factors and aimed to establish a prognostic score of overall survival.

  20. Stanca M, Căpîlna DM, Căpîlna ME. Long-term survival, prognostic factors, and quality of life of patients undergoing pelvic exenteration for cervical cancer. Cancers. 2022;14(9):2346.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Ter Glane L, Hegele A, Wagner U, Boekhoff J. Gynecologic oncology: pelvic exenteration for advanced or recurring cervical cancer–a single center analysis. Cancer Diagn Prognosis. 2022;2(3):308.

    Article  Google Scholar 

  22. Bouraoui I, Bouaziz H, Tounsi N, Ben Romdhane R, Hechiche M, Slimane M, et al. Survival after pelvic exenteration for cervical cancer. J Obstet Gynecol India. 2022;72(1):66–71.

    Article  Google Scholar 

  23. Gheorghe M, Cozlea AL, Kiss SL, Stanca M, Căpîlna ME, Bacalbașa N, et al. Primary pelvic exenteration: our experience with 23 patients from a single institution. Exp Ther Med. 2021;22(4):1–6.

    Article  Google Scholar 

  24. Lewandowska A, Szubert S, Koper K, Koper A, Cwynar G, Wicherek L. Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer. World J Surg Oncol. 2020;18(1):1–9.

    Article  Google Scholar 

  25. Tortorella L, Casarin J, Mara K, Weaver A, Multinu F, Glaser G, et al. Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies. Gynecol Oncol. 2019;152(1):151–6. This is a large single center retrospective study consisting of 138 patients which evaluated risk factors for short term mortality and morbidity after pelvic exeneteration.

  26. Kelly ME, Ryan E, Aalbers A, Abdul AN, Abraham-Nordling M, Alberda W, et al. Pelvic exenteration for advanced nonrectal pelvic malignancy. Ann Surg. 2019;270(5):899–905. This is a large multicenter retrospective study consisting of 2293 patients which evaluated factors associated with survival after pelvic exenteration for nonrectal pelvic malignancies.

  27. Höckel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies. Curr Oncol Rep. 2015;17(3):1–6.

    Article  Google Scholar 

  28. Höckel M, Horn L-C, Einenkel J. (Laterally) Extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. Gynecol Oncol. 2012;127(2):297–302.

    Article  PubMed  Google Scholar 

  29. Sole C, Calvo F, Lozano M, Gonzalez-Bayon L, Gonzalez-Sansegundo C, Alvarez A, et al. External-beam radiation therapy after surgical resection and intraoperative electron-beam radiation therapy for oligorecurrent gynecological cancer. Springer; 2014.

  30. Foley OW, Rauh-Hain JA, Clark RM, Goodman A, Growdon WB, Boruta DM, et al. Intraoperative radiation therapy in the management of gynecologic malignancies. Am J Clin Oncol. 2016;39(4):329–34.

    Article  PubMed  Google Scholar 

  31. Barney BM, Petersen IA, Dowdy SC, Bakkum-Gamez JN, Klein KA, Haddock MG. Intraoperative electron beam radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer. Radiat Oncol. 2013;8(1):1–9.

    Article  Google Scholar 

  32. Calvo F, Sole C, Lozano M, Gonzalez-Bayon L, Gonzalez-Sansegundo C, Alvarez A, et al. Intraoperative electron beam radiotherapy and extended surgical resection for gynecological pelvic recurrent malignancies with and without external beam radiation therapy: long-term outcomes. Gynecol Oncol. 2013;130(3):537–44.

    Article  CAS  PubMed  Google Scholar 

  33. Dowdy SC, Mariani A, Cliby WA, Haddock MG, Petersen IA, Sim FH, et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol. 2006;101(2):280–6.

    Article  PubMed  Google Scholar 

  34. Stelzer KJ, Koh W-J, Greer BE, Cain JM, Tamimi HK, Figge DC, et al. The use of intraoperative radiation therapy in radical salvage for recurrent cervical cancer: outcome and toxicity. Am J Obstet Gynecol. 1995;172(6):1881–8.

    Article  CAS  PubMed  Google Scholar 

  35. Shaw EG, Gunderson LL, Martin JK, Beart RW, Nagorney DM, Podratz K. Peripheral nerve and ureteral tolerance to intraoperative radiation therapy: clinical and dose-response analysis. Radiother Oncol. 1990;18(3):247–55.

    Article  CAS  PubMed  Google Scholar 

  36. Hawighorst-Knapstein S, Fusshoeller C, Franz C, Trautmann K, Schmidt M, Pilch H, et al. The impact of treatment for genital cancer on quality of life and body image—results of a prospective longitudinal 10-year study. Gynecol Oncol. 2004;94(2):398–403.

    Article  PubMed  Google Scholar 

  37. Armbruster SD, Sun CC, Westin SN, Bodurka DC, Ramondetta L, Meyer LA, et al. Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. Gynecol Oncol. 2018;149(3):484–90. This is a prospective longitudinal study which assessed patient reported outcomes in the first year after undergoing pelvic exenteration. It is the first study to evaluate patients’ decision for undergoing surgery post-operatively.

  38. Roos E, De Graeff A, Van Eijkeren M, Boon T, Heintz A. Quality of life after pelvic exenteration. Gynecol Oncol. 2004;93(3):610–4.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA

    Conway Xu MD & Amanika Kumar MD

  2. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA

    Allison E. Garda MD

Authors
  1. Conway Xu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Allison E. Garda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amanika Kumar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amanika Kumar MD.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of theTopical Collection on Gynecologic Cancers

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, C., Garda, A.E. & Kumar, A. R0 Resection in Recurrent Gynecologic Malignancy: Pelvic Exenteration and Beyond. Curr. Treat. Options in Oncol. 24, 262–273 (2023). https://doi.org/10.1007/s11864-023-01055-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01055-6

Keywords

Search

Navigation